Big spike in sales growth for IMC’s Travelan® product
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC; NASDQ: IMRN) has today informed the market of the impressive half year sales results for its over-the-counter gastrointestinal and digestive health supplement Travelan®.
The product saw strong sales growth throughout the first half of the 2018 financial year, both in the US and Australia, with the company reporting A$335,000 in sales in the US market — a 250 per cent increase on the same period last year — and A$579,000 in sales in the Australian market, a 27 per cent increase on the same period last year.
Of course, it should be noted that Immuron is still a speculative stock and anything can happen. Investors should seek professional financial advice if considering this stock for their portfolio.
IMC is a small-cap biotech focused on the treatment of several gut mediated diseases in the realm of oral immunotherapies. Its popular Travelan® product is already available for purchase, while the company’s other immunotherapies — one designed to treat C. Difficile infection and another to treat NASH disease — are still in developmental stages.
In commenting on today’s news, Immuron Marketing Manager David Montgomery said: “Key factors that have positively impacted the ongoing sales momentum include the continued focus on improving the execution of our trade marketing strategy in both the US and Australian markets.
“We are anticipating that the same sales trajectory will continue for Travelan® for the remainder of the 2018 financial year to target our aim of achieving in excess of A$2 million in annual sales for the first time.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
